- Home
- RLMD vs NVCT Comparison
RLMD vs NVCT Comparison
Compare RLMD & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLMD
- NVCT
- Stock Information
- Founded
- RLMD 2004
- NVCT 2020
- Country
- RLMD United States
- NVCT United States
- Employees
- RLMD N/A
- NVCT N/A
- Industry
- RLMD Biotechnology: Pharmaceutical Preparations
- NVCT Medicinal Chemicals and Botanical Products
- Sector
- RLMD Health Care
- NVCT Health Care
- Exchange
- RLMD Nasdaq
- NVCT Nasdaq
- Market Cap
- RLMD 110.6M
- NVCT 119.4M
- IPO Year
- RLMD N/A
- NVCT 2022
- Fundamental
- Price
- RLMD $3.16
- NVCT $5.90
- Analyst Decision
- RLMD Hold
- NVCT Strong Buy
- Analyst Count
- RLMD 2
- NVCT 1
- Target Price
- RLMD $7.50
- NVCT $21.00
- AVG Volume (30 Days)
- RLMD 110.4K
- NVCT 222.2K
- Earning Date
- RLMD 11-07-2024
- NVCT 11-05-2024
- Dividend Yield
- RLMD N/A
- NVCT N/A
- EPS Growth
- RLMD N/A
- NVCT N/A
- EPS
- RLMD N/A
- NVCT N/A
- Revenue
- RLMD N/A
- NVCT N/A
- Revenue This Year
- RLMD N/A
- NVCT N/A
- Revenue Next Year
- RLMD N/A
- NVCT N/A
- P/E Ratio
- RLMD N/A
- NVCT N/A
- Revenue Growth
- RLMD N/A
- NVCT N/A
- 52 Week Low
- RLMD $1.88
- NVCT $5.85
- 52 Week High
- RLMD $7.22
- NVCT $12.10
- Technical
- Relative Strength Index (RSI)
- RLMD 39.24
- NVCT 38.08
- Support Level
- RLMD $3.06
- NVCT $6.00
- Resistance Level
- RLMD $3.43
- NVCT $11.80
- Average True Range (ATR)
- RLMD 0.20
- NVCT 1.22
- MACD
- RLMD -0.04
- NVCT -0.00
- Stochastic Oscillator
- RLMD 16.30
- NVCT 11.16
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.